Simple desensitization protocol for multiple myeloma patients with lenalidomide-induced skin rash: Case series.

Author: HagiharaMasao, InoueMorihiro, MitaMitsuo, OharaShin, SugiTomiyuki, UchidaTomoyuki, YasuTakeo

Paper Details 
Original Abstract of the Article :
WHAT IS KNOWN AND OBJECTIVE: Skin rash is one of the typical side effects of lenalidomide (LEN) treatment. Desensitization therapies have been reported to be effective in patients with severe skin rash caused by LEN. However, they have proved impractical due to the complexity of the protocols. CASE...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/jcpt.13433

データ提供:米国国立医学図書館(NLM)

Lenalidomide Rash: A Gentle Approach to Desensitization

Lenalidomide is a medication used to treat multiple myeloma, but one of its side effects can be a skin rash. This study explores a simple and slow desensitization protocol for patients experiencing this side effect. It’s like carefully navigating a desert path – taking slow, deliberate steps to avoid triggering a reaction.

Finding a Solution: A Gentle Path to Lenalidomide Treatment

The study found that their desensitization protocol was effective in allowing patients to continue receiving lenalidomide without experiencing severe rash reactions. It’s like finding a safe passage through a desert – a way to continue on the path to recovery.

Understanding Side Effects: A Journey of Discovery

This research highlights the importance of personalized treatment approaches and understanding individual patient responses to medication. It’s like exploring a desert landscape – every individual journey is unique, and we need to find the best path for each person.

Dr. Camel's Conclusion

This study offers a valuable approach to managing lenalidomide-induced skin rash, allowing patients to continue receiving this important treatment. It’s like finding a safe oasis in the desert – a place of relief and continued progress.

Date :
  1. Date Completed 2022-02-04
  2. Date Revised 2022-02-04
Further Info :

Pubmed ID

33960000

DOI: Digital Object Identifier

10.1111/jcpt.13433

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.